Fluorine-18 labeling of three novel d-peptides by conjugation with N-succinimidyl-4-[18F]fluorobenzoate and preliminary examination by postmortem whole-hemisphere human brain autoradiography

Nuclear Medicine and Biology

Volumn 39, Issue 3, 2012, Pages 315-323

  Jahan, Mahabuba ^a   Nag, Sangram ^a   Krasikova, Raisa ^a   Weber, Urs ^b   Muhs, Andreas ^b   Pfeifer, Andrea ^b   Spenger, Christian ^c   Willbold, Dieter ^d,e   Gulyás, Balázs ^a   Halldin, Christer ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b AC IMMUNE SA   (Switzerland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d FORSCHUNGSZENTRUM JÜLICH   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Amyloid (A ); Alzheimer's disease (AD); D peptide; Fluorine 18; PET

Indexed keywords

ACI 87; ACI 87 F 18; ACI 88; ACI 88 F 18; ACI 89; ACI 89 F 18; FLUORINE 18; N SUCCINIMIDYL 4 FLUOROBENZOATE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; FEMALE; GRAY MATTER; HEMISPHERE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; NEOCORTEX; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY;

ALZHEIMER DISEASE; AUTORADIOGRAPHY; BENZOATES; BINDING, COMPETITIVE; BRAIN; FEMALE; FLUORINE RADIOISOTOPES; HIPPOCAMPUS; HUMANS; ISOTOPE LABELING; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; OLIGOPEPTIDES; RADIOGRAPHIC IMAGE ENHANCEMENT; RADIOPHARMACEUTICALS; SUCCINIMIDES;

EID: 84858159538     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.09.008     Document Type: Article

References (38)

1. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the US population - prevalence estimates using the 2000 census. Arch Neurol 2003, 60:1119-1122.
2. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
3. Tanzi R.E., Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005, 120:545-555.
4. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997, 18:351-357.
5. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
6. Halldin C., Gulyás B., Farde L. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. Curr Pharm Des 2001, 7:1907-1929.
7. 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004, 45:594-607.
8. Halldin C., Gulyás B., Langer O., Farde L. Brain radioligands - state of the art and new trends. Q J Nucl Med 2001, 45:139-152.
9. Klunk W.E., Engler H., Nordberg A., Wang Y.M., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
10. 11C]SB-13 PET. Am J Geriatr Psychiatry 2004, 12:584-595.
11. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002, 10:24-35.
12. 18F-AV-45 (Florbetapir F 18). J Nucl Med 2010, 51:913-920.
13. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008, 7:129-135.
14. 11C]AZD2184. Eur J Nucl Med Mol Imaging 2009, 36:1859-1863.
15. Någren K., Halldin C., Rinne J.O. Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. Eur J Nucl Med Mol Imaging 2010, 37:1575-1593.
16. Hilbich C., Kisters-Woike B., Reed J., Masters C.L., Beyreuther K. Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease. J Mol Biol 1991, 218:149-163.
17. De Strooper B., König G. Alzheimer's disease - a firm base for drug development. Nature 1999, 402:471-472.
18. Zawadzke L.E., Berg J.M. A racemic protein. J Am Chem Soc 1992, 114:4002-4003.
19. Poduslo J.F., Curran G.L., Kumar A., Frangione B., Soto C. β-Sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J Neurobiol 1999, 39:371-382.
20. Findeis M.A., Musso G.M., Arico-Muendel C.C., Benjamin H.W., Hundal A.M., Lee J.J., et al. Modified-peptide inhibitors of amyloid β-peptide polymerization. Biochemistry 1999, 38:6791-6800.
21. Dintzis H.M., Symer D.E., Dintzis R.Z., Zawadzke L.E., Berg J.M. A comparison of the immunogenicity of a pair of enantiomeric proteins. Proteins 1993, 16:306-308.
22. Schumacher T.N.M., Mayr L.M., Minor D.L., Milhollen M.A., Burgess M.W., Kim P.S. Identification of d-peptide ligands through mirror-image phage display. Science 1996, 271:1854-1857.
23. Hervé M., Maillére B., Mourier G., Texier C., Leroy S., Ménez A. On the immunogenic properties of retro-inverso peptides. Total retro-inversion of T-cell epitopes causes a loss of binding to MHC II molecules. Mol Immunol 1997, 34:157-163.
24. Eckert D.M., Malashkevich V.N., Hong L.H., Carr P.A., Kim P.S. Inhibiting HIV-1 entry: discovery of d-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999, 99:103-115.
25. Funke S.A., Willbold D. Mirror image phage display-a method to generate d-peptide ligands for use in diagnostic or therapeutical applications. Mol Biosyst 2009, 5:783-786.
26. 1-42 by mirror image phage display. ChemBioChem 2003, 4:748-753.
27. Puchtler H., Sweat F. Congo red as a stain for fluorescence microscopy of amyloid. J Histochem Cytochem 1965, 13:693.
28. Klunk W.E., Jacob R.F., Mason R.P. Quantifying amyloid β-peptide (Aβ) aggregation using the Congo red Aβ (CR-Aβ) spectrophotometric assay. Anal Biochem 1999, 266:66-76.
29. Van Groen T., Kadish I., Wiesehan K., Funke S.A., Willbold D. In vitro and in vivo staining characteristics of small, fluorescent, Aβ42-binding d-enantiomeric peptides in transgenic AD mouse models. ChemMed-Chem 2009, 4:276-282.
30. Bartnik D., Funke S.A., Andrei-Selmer L.C., Bacher M., Dodel R., Willbold D. Differently selected d-enantiomeric peptides act on different Aβ species. Rejuvenation Res 2010, 13:202-205.
31. 18F-endothelin-1, a positron emission tomography (PET) radioligand for the endothelin receptor system: radiosynthesis and in vivo imaging using microPET. Clin Sci 2002, 103:4S-8S.
32. 18F]GBR-13119. J Labelled Compd Radiopharm 1989, 27:823-833.
33. 18F]SFB) for protein labeling. J Labelled Compd Radiopharm 2008, 51:68-71.
34. 18F-label the vasoactive transmitter urotensin-II as a ligand for positron emission tomography. Nucl Med Biol 2008, 35:725-731.
35. Hall H., Halldin C., Farde L., Sedvall G. Whole hemisphere autoradiography of the postmortem human brain. Nucl Med Biol 1998, 25:715-719.
36. Hall H., Hurd Y., Pauli S., Halldin C., Sedvall G. Human brain imaging post-mortem - whole hemisphere technologies. Int Rev Psychiatry 2001, 13:12-17.
37. Chételat G., Villemagne V.L., Pike K.E., Ellis K.A., Bourgeat P., Jones G., et al. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain 2011, 134(Pt 3):798-807. Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group.
38. Johnson A.E., Jeppsson F., Sandell J., Wensbo D., Neelissen J.A., Juréus A., et al. AZD2184: a radioligand for sensitive detection of beta-amyloid deposits. J Neurochem 2009, 108:1177-1186.